Progress in the field of precision medicine has changed the landscape of cancer therapy.
Precision medicine is propelled by technologies that enable molecular profiling, genomic …

The RAS oncogene is both the most frequently mutated oncogene in human cancer and the
first confirmed human oncogene to be discovered in 1982. After decades of research, in …

The incidence of rectal cancer is increasing in patients younger than 50 years. Locally
advanced rectal cancer is still treated with neoadjuvant radiation, chemotherapy and …

KRAS mutations occur in a quarter of all of human cancers, yet no selective drug has been
approved to treat these tumors. Despite the recent development of drugs that block KRAS …

Purpose With prospective clinical sequencing of tumors emerging as a mainstay in cancer
care, an urgent need exists for a clinical support tool that distills the clinical implications …

PURPOSE BRAF V600 mutations occur in many childhood cancers, including approximately
20% of low-grade gliomas (LGGs). Here, we describe a phase I/II study establishing …

Abstract The RAS–RAF–MEK–ERK signaling cascade is among the most frequently mutated
pathways in human cancer. Approximately 50% of melanoma patients possess a druggable …

RAS genes are the most commonly mutated oncogenes in cancer, but effective therapeutic
strategies to target RAS-mutant cancers have proved elusive. A key aspect of this challenge …

Background Effective medical therapies are lacking for the treatment of neurofibromatosis
type 1–related plexiform neurofibromas, which are characterized by elevated RAS–mitogen …

In recent years, the high heterogeneity of colorectal cancer (CRC) has become evident.
Hence, biomarkers need to be developed that enable the stratification of patients with CRC …